AOP Health’s First-in-class Investigational Cancer Drug Enters Phase 1 Trial
AOP Orphan Pharmaceuticals GmbH (AOP Health), in collaboration with Leukos Biotech, has reached a significant milestone in cancer therapy. The
Read more
Latest
AstraZeneca’s FluMist Influenza Vaccine FDA Approved for Self-Administration
In a landmark approval, the U.S. Food and Drug Administration (FDA) has cleared AstraZeneca’s FluMist, the only influenza vaccine that
Read more
GSK Announces Positive Phase III Trial Results for Nucala in COPD Patients
GSK has announced promising headline results from its Phase III clinical trial, MATINEE, which evaluated the efficacy of Nucala (mepolizumab)
Read more
Novavax Wins FDA Emergency Approval for 2024-2025 COVID-19 Vaccine Formula
Novavax, a global leader in protein-based vaccines, has announced that its updated COVID-19 vaccine, Adjuvanted (2024-2025 Formula) (NVX-CoV2705), has received
Read more
FDA Approves Pfizer and BioNTech’s Omicron KP.2-adapted COVID-19 Vaccine
Pfizer and BioNTech have announced that the U.S. Food and Drug Administration (FDA) has approved their supplemental Biologics License Application
Read more
Sangamo and Genentech to Develop Genomic Medicines for Neurodegenerative Diseases
Sangamo Therapeutics Enters License Agreement with Genentech to Develop Genomic Medicines for Neurodegenerative Diseases Sangamo Therapeutics, Inc., a leader in
Read more
J& J Announces Positive Phase 3 Trial Results for Nipocalimab in gMG
Johnson & Johnson (NYSE: JNJ) has announced promising outcomes from its Phase 3 Vivacity-MG study, evaluating Nipocalimab in patients with
Read more
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron JN.1-Adapted COVID-19 Vaccine in the EU
Pfizer and BioNTech have received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the
Read more
New 3D Cell-based Model Unveils Insights on Immune Cells in Alzheimer’s Disease
Researchers have devised a novel human 3D model for Alzheimer’s Disease, enabling the study of immune cell involvement in the
Read more
GSK’s ADC Blenrep Cuts Risk of Multiple Myeloma Progression by Nearly 50% in Phase III Trial
British pharma giant GSK has announced positive results from an interim analysis of the DREAMM-8 phase III head-to-head trial evaluating Blenrep (belantamab
Read more